|
Nevada
(State or Other
Jurisdiction of
Incorporation)
|
1-10245
(Commission File
Number)
|
95-1480559
(I.R.S. Employer
Identification No.)
|
|
2500 McClellan Avenue, Suite 350
|
||
|
Pennsauken, NJ
|
08109-4613
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
Common Stock, par value $0.05 per share
|
RCMT
|
The NASDAQ Stock Market LLC
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
|
Exhibit Number
|
|
|
Press Release by the Registrant, dated May 13, 2021, furnished in
accordance with Item 2.02 of this Current Report on Form 8-K.
|

|
RCM Technologies, Inc.
|
Tel: 856.356.4500
|
Corporate Contacts:
|
|
2500 McClellan Avenue
|
Fax: 856.356.4600
|
Bradley S. Vizi
|
|
Pennsauken, NJ 08109
|
Executive Chairman
|
|
|
www.rcmt.com
|
Kevin D. Miller
|
|
|
Chief Financial Officer
|
|
Thirteen Week Period Ended
|
||||
|
April 3,
2021
|
March 28,
2020
|
|||
|
Revenue
|
$44,549
|
$45,033
|
||
|
Cost of services
|
33,699
|
34,190
|
||
|
Gross profit
|
10,850
|
10,843
|
||
|
Selling, general and administrative
|
9,069
|
10,237
|
||
|
Depreciation and amortization of property and equipment
|
266
|
255
|
||
|
Amortization of acquired intangible assets
|
80
|
80
|
||
|
Write-off of receivables and professional fees
incurred related to arbitration
|
-
|
8,047
|
||
|
Tax credit professional fees
|
60
|
-
|
||
|
Operating income (loss)
|
1,375
|
(7,776
|
)
|
|
|
Other expense, net
|
12
|
409
|
||
|
Income (loss) before income taxes
|
1,363
|
(8,185
|
)
|
|
|
Income tax expense (benefit)
|
356
|
(2,240
|
)
|
|
|
Net income (loss)
|
$1,007
|
($5,945
|
)
|
|
|
Diluted net earnings (loss) per share data
|
$0.08
|
($0.45
|
)
|
|
|
April 3,
2021
|
January 2,
2021
|
||
|
(Unaudited)
|
|||
|
Cash and cash equivalents
|
$678
|
$734
|
|
|
Accounts receivable, net
|
$45,282
|
$36,007
|
|
|
Total current assets
|
$54,108
|
$43,934
|
|
|
Total assets
|
$77,770
|
$68,339
|
|
|
Total current liabilities
|
$27,762
|
$28,741
|
|
|
Borrowing under line of credit
|
$22,029
|
$11,890
|
|
|
Net debt (line of credit less cash)
|
$21,351
|
$11,156
|
|
|
Total liabilities
|
$54,844
|
$46,101
|
|
|
Stockholders’ equity
|
$22,926
|
$22,238
|
|
Thirteen
Week Period Ended
|
||||
|
April 3,
2021
|
March 28,
2020
|
|||
|
GAAP net income (loss)
|
$1,007
|
($5,945
|
)
|
|
|
Income tax expense (benefit)
|
356
|
(2,240
|
)
|
|
|
Interest expense
|
121
|
340
|
||
|
Change in fair value of contingent consideration
|
26
|
36
|
||
|
Depreciation of property and equipment
|
266
|
255
|
||
|
Amortization of acquired intangible assets
|
80
|
80
|
||
|
EBITDA (non-GAAP)
|
$1,856
|
($7,474
|
)
|
|
|
Adjustments
|
||||
|
Write-off of receivables and professional fees
incurred related to arbitration
|
-
|
8,047
|
||
|
Tax credit professional fees
|
60
|
-
|
||
|
(Gain) loss on foreign currency transactions
|
(135
|
)
|
33
|
|
|
Adjusted EBITDA (non-GAAP)
|
$1,781
|
$606
|
||
|
Thirteen Week Period Ended
|
|||||
|
April 3,
2021
|
March 28,
2020
|
||||
|
Net income (loss)
|
$1,007
|
($5,945
|
)
|
||
|
Adjustments to reconcile net income to cash
used in operating activities
|
886
|
6,015
|
|||
|
Changes in operating assets and liabilities:
|
|||||
|
Accounts receivable
|
(9,085
|
)
|
974
|
||
|
Prepaid expenses and other current assets
|
582
|
166
|
|||
|
Net of transit accounts receivable and payable
|
(1,802
|
)
|
973
|
||
|
Accounts payable and accrued expenses
|
(588
|
)
|
(6
|
)
|
|
|
Accrued payroll and related costs
|
187
|
(1,289
|
)
|
||
|
Right of use assets
|
146
|
304
|
|||
|
Right of use liabilities
|
(366
|
)
|
(284
|
)
|
|
|
Income taxes payable
|
(157
|
)
|
21
|
||
|
Total adjustments
|
(10,197
|
)
|
6,874
|
||
|
Cash (used in) provided by operating activities
|
(9,190
|
)
|
929
|
||
|
Net cash used in investing activities
|
(47
|
)
|
(35
|
)
|
|
|
Net cash provided by (used in) financing activities
|
9,315
|
(1,934
|
)
|
||
|
Effect of exchange rate changes
|
(134
|
)
|
(165
|
)
|
|
|
Decrease in cash and cash equivalents
|
($56
|
)
|
($1,205
|
)
|
|
|
Thirteen Week Period Ended April 3, 2021
|
||||||||
|
Engineering
|
Specialty
Health Care
|
Information
Technology
|
Consolidated
|
|||||
|
Revenue
|
$14,466
|
$21,137
|
$8,946
|
$44,549
|
||||
|
Cost of services
|
11,260
|
16,099
|
6,340
|
33,699
|
||||
|
Gross profit
|
$3,206
|
$5,038
|
$2,606
|
$10,850
|
||||
|
Gross profit margin
|
22.2
|
%
|
23.8
|
%
|
29.1
|
%
|
24.4
|
%
|
|
Thirteen Week Period Ended March 28, 2020
|
||||||||
|
Engineering
|
Specialty
Health Care
|
Information
Technology
|
Consolidated
|
|||||
|
Revenue
|
$14,163
|
$22,197
|
$8,673
|
$45,033
|
||||
|
Cost of services
|
10,205
|
17,812
|
6,173
|
34,190
|
||||
|
Gross profit
|
$3,958
|
$4,385
|
$2,500
|
$10,843
|
||||
|
Gross profit margin
|
27.9
|
%
|
19.8
|
%
|
28.8
|
%
|
24.1
|
%
|